5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial

Roth, Arnaud; Maibach, R; Fazio, N; Sessa, C; Stupp, R; Morant, R; Herrmann, R; Borner, M M; Goldhirsch, A; de Braud, F

doi:10.1093/annonc/mdh187

Advanced search

Browse by...

Deposit

Highlights

More informations

Title		5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial
Authors		Roth, Arnaud Maibach, R Fazio, N Sessa, C Stupp, R Morant, R Herrmann, R Borner, M M Goldhirsch, A de Braud, F show all authors [1 - 10]
Published in		Annals of oncology. 2004, vol. 15, no. 5, p. 759-64
Abstract		A phase I-II multicenter trial was conducted to define the maximum tolerated dose (MTD) according to tolerance and toxicity (primary objective), as well as to describe the clinical activity, in terms of response and survival (secondary objectives), of a combination of 5-fluorouracil (5-FU) in protracted continuous intravenous infusion (p.i.v.) with docetaxel and cisplatin for patients with advanced gastric cancer.
Keywords		Adult — Aged — Antineoplastic Combined Chemotherapy Protocols/therapeutic use — Carcinoma/drug therapy/pathology — Cisplatin/administration & dosage — Female — Fluorouracil/administration & dosage — Humans — Infusions, Intravenous — Male — Maximum Tolerated Dose — Middle Aged — Stomach Neoplasms/drug therapy/pathology — Survival Analysis — Taxoids/administration & dosage
Identifiers		DOI: 10.1093/annonc/mdh187 PMID: 15111343
Full text		Article (Published version) (94 Kb) - Free access Other version: http://annonc.oxfordjournals.org/content/15/5/759.long
Structures		Faculté de médecine / Section de médecine clinique / Département de chirurgie
Research group		Groupe Roth Arnaud (oncologie) (285)
Citation (ISO format)		ROTH, Arnaud et al. 5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial. In: Annals of oncology, 2004, vol. 15, n° 5, p. 759-64. doi: 10.1093/annonc/mdh187 https://archive-ouverte.unige.ch/unige:42140